Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
Eisai, BioArctic’s long-standing partner, has submitted a Marketing Authorisation Variation to the European Medicines Agency to allow a once-every-four-weeks intravenous maintenance dosing regimen for Alzheimer’s drug Leqembi (lecanemab), following an initial 18‑month period of biweekly infusions in patients with early-stage disease. The move, which aligns the EU regimen with maintenance dosing already approved in major markets such as the U.S., U.K. and China and complements a growing portfolio of subcutaneous formulations and ongoing late-stage trials, underscores BioArctic’s strengthening position in disease-modifying Alzheimer’s therapies and could expand treatment convenience and uptake, bolstering future royalty and milestone revenue potential for the Swedish biotech as it prepares joint commercialization with Eisai in the Nordic region.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK387.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish research-based biopharmaceutical company focused on innovative treatments to delay or halt the progression of neurodegenerative diseases, particularly Alzheimer’s, Parkinson’s and ALS. The company invented Leqembi (lecanemab), the first drug shown to slow disease progression and reduce cognitive impairment in early Alzheimer’s, and collaborates with Eisai on its global development and commercialization while retaining commercialization rights in the Nordic region and advancing a broader pipeline leveraging its BrainTransporter technology to improve antibody delivery across the blood-brain barrier.
YTD Price Performance: 0.06%
Average Trading Volume: 203,205
Technical Sentiment Signal: Buy
Current Market Cap: SEK27.57B
For detailed information about BIOA.B stock, go to TipRanks’ Stock Analysis page.